Stoke Therapeutics shares are trading higher after Cantor Fitzgerald maintained an Overweight rating on the stock and raised its price target from $20 to $25.
Portfolio Pulse from Benzinga Newsdesk
Stoke Therapeutics shares are trading higher after Cantor Fitzgerald maintained an Overweight rating on the stock and raised its price target from $20 to $25.
May 23, 2023 | 3:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald maintained an Overweight rating on Stoke Therapeutics and raised its price target from $20 to $25, resulting in higher trading.
Cantor Fitzgerald, a well-known financial services firm, maintained an Overweight rating on Stoke Therapeutics and raised its price target from $20 to $25. This positive outlook from a reputable analyst is likely to boost investor confidence in the stock, leading to higher trading and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100